Spectral AI (NASDAQ:MDAI – Get Free Report) is one of 225 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its peers? We will compare Spectral AI to related companies based on the strength of its institutional ownership, valuation, earnings, analyst recommendations, dividends, risk and profitability.
Insider and Institutional Ownership
67.1% of Spectral AI shares are owned by institutional investors. Comparatively, 47.6% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 56.7% of Spectral AI shares are owned by company insiders. Comparatively, 15.8% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings and Valuation
This table compares Spectral AI and its peers top-line revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Spectral AI | $18.06 million | -$20.85 million | -0.95 |
Spectral AI Competitors | $876.42 million | $48.15 million | -8.79 |
Risk & Volatility
Spectral AI has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, Spectral AI’s peers have a beta of 0.54, meaning that their average share price is 46% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and recommmendations for Spectral AI and its peers, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Spectral AI | 0 | 0 | 3 | 1 | 3.25 |
Spectral AI Competitors | 1668 | 4413 | 8455 | 250 | 2.49 |
Spectral AI presently has a consensus price target of $4.50, suggesting a potential upside of 254.33%. As a group, “Surgical & medical instruments” companies have a potential upside of 19.18%. Given Spectral AI’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Spectral AI is more favorable than its peers.
Profitability
This table compares Spectral AI and its peers’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Spectral AI | -89.85% | N/A | -104.64% |
Spectral AI Competitors | -578.37% | -140.27% | -25.88% |
Summary
Spectral AI beats its peers on 10 of the 13 factors compared.
Spectral AI Company Profile
Spectral AI, Inc., an artificial intelligence (AI) company, focuses on developing predictive medical diagnostics in the United States. The company develops medical diagnostics for faster and accurate treatment decisions in wound care with applications involving patients with burns and diabetic foot ulcers. Its products include DeepView System, a predictive analytics platform integrated with the predictive AI-Burn, which combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential and offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention; and DeepView SnapShot M, a handheld, portable, and wireless diagnostic tool, that provides a potential enhanced and expanded use for the government and emergency care, first responders, and potentially home health care professionals. The company is headquartered in Dallas, Texas.
Receive News & Ratings for Spectral AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral AI and related companies with MarketBeat.com's FREE daily email newsletter.